{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:36:52Z","timestamp":1793741812833,"version":"4.6.1"},"reference-count":272,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cyto.2023.156287","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T14:48:16Z","timestamp":1687790896000},"page":"156287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["Emerging aspects of cytokine storm in COVID-19: The role of proinflammatory cytokines and therapeutic prospects"],"prefix":"10.1016","volume":"169","author":[{"given":"Renu","family":"Dharra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kumar Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2023.156287_b0005","first-page":"27(2)","article-title":"Potential for global spread of a novel coronavirus from China","author":"Bogoch Isaac","year":"2020","journal-title":"J. Travel Med."},{"key":"10.1016\/j.cyto.2023.156287_b0010","doi-asserted-by":"crossref","unstructured":"W. Chen, H. Peter W, H. Frederick G, G. George F, A novel coronavirus outbreak of global health concern, Lancet (London, England) 395 (10223) (2020) 470\u2013473, doi: 10.1016\/S0140-6736(20)30185-9.","DOI":"10.1016\/S0140-6736(20)30185-9"},{"key":"10.1016\/j.cyto.2023.156287_b0015","unstructured":"WHO, Novel Coronavirus (2019-nCoV) SITUATION REPORT \u2013 1, 2020."},{"issue":"14","key":"10.1016\/j.cyto.2023.156287_b0020","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2020.2565","article-title":"Presumed asymptomatic carrier transmission of COVID-19","volume":"323","author":"Yan","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.cyto.2023.156287_b0025","article-title":"The association between domestic train transportation and novel coronavirus (2019-nCoV) outbreak in China from 2019 to 2020: A data-driven correlational report","volume":"33","author":"Shi","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhin.2020.02.021","article-title":"Association between 2019-nCoV transmission and N95 respirator use","volume":"105","author":"Wang","year":"2020","journal-title":"J. Hosp. Infect."},{"issue":"June","key":"10.1016\/j.cyto.2023.156287_b0035","first-page":"1","article-title":"The COVID-19 cytokine storm; What we know so far","volume":"11","author":"Dina","year":"2020","journal-title":"Front. Immunol."},{"issue":"November","key":"10.1016\/j.cyto.2023.156287_b0040","first-page":"1","article-title":"Controlling cytokine storm is vital in COVID-19","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"issue":"10223","key":"10.1016\/j.cyto.2023.156287_b0045","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Nanshan","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cyto.2023.156287_b0050","doi-asserted-by":"crossref","unstructured":"Department of Error, Lancet (London, England) 395 (10223) (2020) 496, doi: 10.1016\/S0140-6736(20)30252-X.","DOI":"10.1016\/S0140-6736(20)30250-6"},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0055","doi-asserted-by":"crossref","first-page":"E113","DOI":"10.1148\/radiol.2020200527","article-title":"Essentials for radiologists on COVID-19: an update-radiology scientific expert panel","volume":"296","author":"Kanne Jeffrey","year":"2020","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0060","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.2214\/AJR.20.22976","article-title":"Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study","volume":"214","author":"Wei","year":"2020","journal-title":"AJR Am. J. Roentgenol."},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0065","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Rudragouda","year":"2017","journal-title":"Semin. Immunopathol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Alexander","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1 Pt 2","key":"10.1016\/j.cyto.2023.156287_b0075","first-page":"1216","article-title":"Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1","volume":"25","author":"Ferrara","year":"1993","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.cyto.2023.156287_b0080","article-title":"The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?","volume":"153","author":"Dounia","year":"2021","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.cyto.2023.156287_b0085","doi-asserted-by":"crossref","unstructured":"Mehta Puja, McAuley Daniel F, Brown Michael, Sanchez Emilie, Tattersall Rachel S, Manson Jessica J, et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet (London, England) 395 (10229) (2020) 1033\u20131034, doi: 10.1016\/S0140-6736(20)30628-0.","DOI":"10.1016\/S0140-6736(20)30628-0"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.chom.2022.11.012","article-title":"Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2","volume":"31","author":"Panke","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cyto.2023.156287_b0095","unstructured":"Prater Erin, \u2018Everyone is kind of tired and has given up\u2019 on COVID. But this new variant is \u2018one to watch,\u2019 the WHO says. Available from: <https:\/\/fortune.com\/well\/2023\/03\/31\/arcturus-covid-variant-watch-who-world-health-organization-xbb116-omicron-wave\/ 2023>."},{"issue":"10223","key":"10.1016\/j.cyto.2023.156287_b0100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Chaolin","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cyto.2023.156287_b0105","first-page":"E005","article-title":"Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia","volume":"43","author":"Chen","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.cyto.2023.156287_b0110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijid.2020.04.041","article-title":"Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019","volume":"95","author":"Zhe","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.cyto.2023.156287_b0115","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Marie","year":"2020","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0120","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Qiurong","year":"2020","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0125","article-title":"Cytokine Storm in COVID-19: Immunopathogenesis and Therapy","volume":"58","author":"Christian","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0130","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1440-1711.1998.00757.x","article-title":"Cytokines: principles and prospects","volume":"76","author":"Kelso","year":"1998","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.cyto.2023.156287_b0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/02648725.2013.801236","article-title":"Post-transcriptional regulation of cytokine mRNA controls the initiation and resolution of inflammation","volume":"29","author":"Takashi","year":"2013","journal-title":"Biotechnol. Genet. Eng. Rev."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2613.2001.iep192.x","article-title":"The functions of cytokines and their uses in toxicology","volume":"82","author":"Foster","year":"2001","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.cyto.2023.156287_b0145","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0150","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4049\/jimmunol.142.2.549","article-title":"IL-1 stimulates IL-6 production in endothelial cells","volume":"142","author":"Sironi","year":"1989","journal-title":"J. Immunol."},{"issue":"12 Suppl","key":"10.1016\/j.cyto.2023.156287_b0155","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1097\/01.CCM.0000185500.11080.91","article-title":"Interleukin-1beta","volume":"33","author":"Dinarello","year":"2005","journal-title":"Crit. Care Med."},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0160","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/thorax.57.5.383","article-title":"Exhaled nitric oxide correlates with airway eosinophils in childhood asthma","volume":"57","author":"Warke","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.cyto.2023.156287_b0165","doi-asserted-by":"crossref","unstructured":"Chen I-Yin, Moriyama Miyu, Chang Ming-Fu, Ichinohe Takeshi, Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome, Front. Microbiol. 10 (2019) 50, doi: 10.3389\/fmicb.2019.00050.","DOI":"10.3389\/fmicb.2019.00050"},{"issue":"6504","key":"10.1016\/j.cyto.2023.156287_b0170","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"J\u00e9r\u00f4me","year":"2020","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.cyto.2023.156287_b0175","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones Simon","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The biology of interleukin-6","volume":"74","author":"Kishimoto","year":"1989","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0185","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj2650621","article-title":"Interleukin-6 and the acute phase response","volume":"265","author":"Heinrich","year":"1990","journal-title":"Biochem. J"},{"issue":"10","key":"10.1016\/j.cyto.2023.156287_b0190","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Toshio","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b0195","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/cid\/ciaa449","article-title":"Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically Ill patients with coronavirus disease 2019","volume":"71","author":"Xiaohua","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0200","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","article-title":"Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19","volume":"146","author":"Tobias","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0205","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal Bharat","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.cyto.2023.156287_b0210","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Chuan","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0215","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen Guang","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2023.156287_b0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","article-title":"Regulation of interferon-gamma during innate and adaptive immune responses","volume":"96","author":"Schoenborn Jamie","year":"2007","journal-title":"Adv. Immunol."},{"issue":"7","key":"10.1016\/j.cyto.2023.156287_b0225","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1084\/jem.20041463","article-title":"Interferon-gamma acts directly on CD8+ T cells to increase their abundance during virus infection","volume":"201","author":"Whitmire Jason","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2023.156287_b0230","doi-asserted-by":"crossref","unstructured":"Gadotti Ana Carolina, de Castro Deus Marina, Telles Joao Paulo, Wind Rafael, Goes Marina, Garcia Charello Ossoski Roberta, et al., IFN-\u03b3 is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection, Virus Res. 289 (2020) 198171, doi: 10.1016\/j.virusres.2020.198171.","DOI":"10.1016\/j.virusres.2020.198171"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0235","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Rajendra","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0240","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.cr.7310017","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know","volume":"16","author":"Yufang","year":"2006","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0245","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S2213-2600(21)00539-7","article-title":"Stimulating severe COVID-19: the potential role of GM-CSF antagonism","volume":"10","author":"Leavis Helen","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0250","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4049\/jimmunol.1302734","article-title":"IL-1\u03b2 promotes the differentiation of polyfunctional human CCR6+CXCR3+ Th1\/17 cells that are specific for pathogenic and commensal microbes","volume":"193","author":"Thomas","year":"2014","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0255","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4049\/jimmunol.142.3.813","article-title":"Prostaglandin E2-dependent induction of granulocyte-macrophage colony-stimulating factor secretion by cloned murine helper T cells","volume":"142","author":"Quill","year":"1989","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b0260","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1471-4906(02)02260-3","article-title":"GM-CSF in inflammation and autoimmunity","volume":"23","author":"Hamilton","year":"2002","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0265","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1034\/j.1399-3003.2000.15e14.x","article-title":"G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome","volume":"15","author":"Aggarwal","year":"2000","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00003246-200001000-00001","article-title":"Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte\/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome","volume":"28","author":"Matute-Bello","year":"2000","journal-title":"Crit. Care Med."},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0275","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000492950","article-title":"The pathogenic involvement of neutrophils in acute respiratory distress syndrome and transfusion-related acute lung injury","volume":"45","author":"Johan","year":"2018","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.cyto.2023.156287_b0280","doi-asserted-by":"crossref","unstructured":"Bonaventura Aldo, Montecucco Fabrizio, Dallegri Franco, Carbone Federico, L\u00fcscher Thomas F, Camici Giovanni G, et al., Novel findings in neutrophil biology and their impact on cardiovascular disease, Cardiovasc Res. 115 (8) (2019), 1266\u20131285, doi: 10.1093\/cvr\/cvz084.","DOI":"10.1093\/cvr\/cvz084"},{"key":"10.1016\/j.cyto.2023.156287_b0285","doi-asserted-by":"crossref","unstructured":"M. Lang Frederick, M.-C. Lee Kevin, R. Teijaro John, B. Burkhard, A. Hamilton John, GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches, Nat. Rev. Immunol. 20 (8) (2020) 507\u2013514, doi: 10.1038\/s41577-020-0357-7.","DOI":"10.1038\/s41577-020-0357-7"},{"key":"10.1016\/j.cyto.2023.156287_b0290","article-title":"Pivotal roles of GM-CSF in autoimmunity and inflammation","volume":"2015","author":"Aoi","year":"2015","journal-title":"Mediators Inflamm."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0295","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/nsr\/nwaa041","article-title":"Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients","volume":"7","author":"Zhou Yonggang","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.cyto.2023.156287_b0300","doi-asserted-by":"crossref","unstructured":"Crotti Chiara, Agape Elena, Becciolini Andrea, Biggioggero Martina, Favalli Ennio Giulio, Targeting granulocyte-monocyte colony-stimulating factor signaling in rheumatoid arthritis: future prospects, Drugs 79 (16) (2019) 1741\u20131755, doi: 10.1007\/s40265-019-01192-z.","DOI":"10.1007\/s40265-019-01192-z"},{"key":"10.1016\/j.cyto.2023.156287_b0305","doi-asserted-by":"crossref","unstructured":"van der Poll Tom, van de Veerdonk Frank L, Scicluna Brendon P, Netea Mihai G., The immunopathology of sepsis and potential therapeutic targets, Nat. Rev. Immunol. 17 (7) (2017) 407\u2013420, doi: 10.1038\/nri.2017.36.","DOI":"10.1038\/nri.2017.36"},{"key":"10.1016\/j.cyto.2023.156287_b0310","first-page":"379","article-title":"Hematopoietic growth-factor signal transduction and regulation of gene expression","volume":"49","author":"Farrar","year":"1990","journal-title":"Immunol. Ser."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0315","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/S0021-9258(18)71855-3","article-title":"Purification and properties of colony-stimulating factor from mouse lung-conditioned medium","volume":"252","author":"Burgess","year":"1977","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0320","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood.V56.6.947.947","article-title":"The nature and action of granulocyte-macrophage colony stimulating factors","volume":"56","author":"Burgess","year":"1980","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0325","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.it.2012.08.006","article-title":"Colony stimulating factors and myeloid cell biology in health and disease","volume":"34","author":"Hamilton John","year":"2013","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/stem.5530050102","article-title":"Granulocyte colony-stimulating factor and differentiation-induction in myeloid leukemic cells","volume":"5","author":"Nicola","year":"1987","journal-title":"Int. J. Cell Cloning"},{"key":"10.1016\/j.cyto.2023.156287_b0335","doi-asserted-by":"crossref","unstructured":"Guilliams Martin, De Kleer Ism\u00e9, Henri Sandrine, Post Sijranke, Vanhoutte Leen, De Prijck Sofie, et al., 2013. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF, J. Exp. Med. 210 (10), 1977\u20131992, doi: 10.1084\/jem.20131199.","DOI":"10.1084\/jem.20131199"},{"key":"10.1016\/j.cyto.2023.156287_b0340","doi-asserted-by":"crossref","unstructured":"Trapnell Bruce C, Nakata Koh, Bonella Francesco, Campo Ilaria, Griese Matthias, Hamilton John, et al., Pulmonary alveolar proteinosis, Nat. Rev. Dis. Prim. 5 (1) (2019) 16, doi: 10.1038\/s41572-019-0066-3.","DOI":"10.1038\/s41572-019-0066-3"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0345","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa062505","article-title":"GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis","volume":"356","author":"Kanji","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.cyto.2023.156287_b0350","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.201002-0271OC","article-title":"Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy","volume":"182","author":"Takuji","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.cyto.2023.156287_b0355","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S2213-2600(18)30043-2","article-title":"Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach","volume":"6","author":"Anupam","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cyto.2023.156287_b0360","doi-asserted-by":"crossref","unstructured":"Bonaventura Aldo, Vecchi\u00e9 Alessandra, Wang Tisha S, Lee Elinor, Cremer Paul C, Carey Brenna, et al., Targeting GM-CSF in COVID-19 Pneumonia: rationale and strategies, Front. Immunol. 11 (2020) 1625, doi: 10.3389\/fimmu.2020.01625.","DOI":"10.3389\/fimmu.2020.01625"},{"key":"10.1016\/j.cyto.2023.156287_b0365","doi-asserted-by":"crossref","unstructured":"Achuthan Adrian, Cook Andrew D, Lee Ming-Chin, Saleh Reem, Khiew Hsu-Wei, Chang Melody W N, et al., Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation, J. Clin. Invest. 126 (9) (2016) 3453\u20133466, doi: 10.1172\/JCI87828.","DOI":"10.1172\/JCI87828"},{"key":"10.1016\/j.cyto.2023.156287_b0370","doi-asserted-by":"crossref","unstructured":"F.M. Rollwagen, T.A. Davis, Y.-Y. Li, N.D. Pacheco, X.-L. Zhu, Orally administered IL-6 induces elevated intestinal GM-CSF gene expression and splenic CFU-GM, Cytokine 27 (4\u20135) (n.d.) 107\u2013112, doi: 10.1016\/j.cyto.2004.03.019.","DOI":"10.1016\/j.cyto.2004.03.019"},{"key":"10.1016\/j.cyto.2023.156287_b0375","doi-asserted-by":"crossref","unstructured":"Berclaz Pierre-Yves, Carey Brenna, Fillipi Marie-Dominique, Wernke-Dollries Kara, Geraci Nick, Cush Stephanie, et al., GM-CSF regulates a PU.1-dependent transcriptional program determining the pulmonary response to LPS, Am. J. Respir Cell Mol. Biol. 36 (1) (2007) 114\u2013121, doi: 10.1165\/rcmb.2006-0174OC.","DOI":"10.1165\/rcmb.2006-0174OC"},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0380","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1074-7613(01)00218-7","article-title":"GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1","volume":"15","author":"Shibata","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2023.156287_b0385","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/1742-2094-9-268","article-title":"GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia","volume":"9","author":"Bijay","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.cyto.2023.156287_b0390","doi-asserted-by":"crossref","unstructured":"Sorgi Carlos Arterio, Rose Stephanie, Court Nathalie, Carlos Daniela, Paula-Silva Francisco Wanderley Garcia, Assis Patricia Aparecida, et al., GM-CSF priming drives bone marrow-derived macrophages to a pro-inflammatory pattern and downmodulates PGE2 in response to TLR2 ligands, PLoS One 7 (7) (2012) e40523, doi: 10.1371\/journal.pone.0040523.","DOI":"10.1371\/journal.pone.0040523"},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b0395","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.4049\/jimmunol.178.8.5245","article-title":"Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation","volume":"178","author":"Fleetwood Andrew","year":"2007","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0400","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/ni.1990","article-title":"IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses","volume":"12","author":"Thomas","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2023.156287_b0405","doi-asserted-by":"crossref","unstructured":"A.W. Verreck Frank, de Boer Tjitske, M.L. Langenberg Dennis, A. Hoeve Marieke, Kramer Matthijs, Vaisberg Elena, et al., Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria, Proc. Natl. Acad. Sci. U. S. A. 101 (13) (2004) 4560\u20134565, doi: 10.1073\/pnas.0400983101.","DOI":"10.1073\/pnas.0400983101"},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0410","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cellsig.2013.11.004","article-title":"Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways","volume":"26","author":"Dexi","year":"2014","journal-title":"Cell. Signal."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0415","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ni.2031","article-title":"The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF","volume":"12","author":"Mohamed","year":"2011","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0420","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ni.2027","article-title":"ROR\u03b3t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation","volume":"12","author":"Laura","year":"2011","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b0425","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.30332","article-title":"Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis","volume":"63","author":"Lorenzo","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2023.156287_b0430","doi-asserted-by":"crossref","unstructured":"Piper Christopher, Pesenacker Anne M, Bending David, Thirugnanabalan Balathas, Varsani Hemlata, Wedderburn Lucy R, et al., T cell expression of granulocyte-macrophage colony-stimulating factor in juvenile arthritis is contingent upon Th17 plasticity, Arthritis Rheumatol (Hoboken, NJ) 66 (7) (2014) 1955\u20131960, doi: 10.1002\/art.38647.","DOI":"10.1002\/art.38647"},{"key":"10.1016\/j.cyto.2023.156287_b0435","doi-asserted-by":"crossref","unstructured":"Kebir Hania, Ifergan Igal, Alvarez Jorge Ivan, Bernard Monique, Poirier Jos\u00e9e, Arbour Nathalie, et al., Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis, Ann Neurol 66 (3) (2009) 390\u2013402, doi: 10.1002\/ana.21748.","DOI":"10.1002\/ana.21748"},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0440","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.20091844","article-title":"GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization","volume":"207","author":"King Irah","year":"2010","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0445","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4049\/jimmunol.165.1.49","article-title":"Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand","volume":"165","author":"Daro","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2023.156287_b0450","doi-asserted-by":"crossref","unstructured":"Zhan Yifan, Carrington Emma M, van Nieuwenhuijze Annemarie, Bedoui Sammy, Seah Shirley, Xu Yuekang, et al., GM-CSF increases cross-presentation and CD103 expression by mouse CD8+ spleen dendritic cells, Eur. J. Immunol. 41 (9) (2011) 2585\u20132595, doi: 10.1002\/eji.201141540.","DOI":"10.1002\/eji.201141540"},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0455","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/08977190412331279881","article-title":"GM-CSF biology","volume":"22","author":"Hamilton John","year":"2004","journal-title":"Growth Factors"},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0460","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(87)90136-X","article-title":"Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage","volume":"51","author":"Lang","year":"1987","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0465","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/08916930290005954","article-title":"Organ-specific autoimmunity in granulocyte macrophage-colony stimulating factor (GM-CSF) deficient mice","volume":"35","author":"Frank","year":"2002","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0470","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/j.1460-2075.1989.tb03396.x","article-title":"A lethal myeloproliferative syndrome in mice transplanted with bone marrow cells infected with a retrovirus expressing granulocyte-macrophage colony stimulating factor","volume":"8","author":"Johnson","year":"1989","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b0475","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/jir.2014.0149","article-title":"Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy","volume":"35","author":"Palash","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.cyto.2023.156287_b0480","doi-asserted-by":"crossref","unstructured":"Nemunaitis John, Sterman Daniel, Jablons David, Smith John W, Fox Bernard, Maples Phil, et al., Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer, J. Natl. Cancer Inst. 96 (4) (2004) 326\u2013331, doi: 10.1093\/jnci\/djh028.","DOI":"10.1093\/jnci\/djh028"},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0485","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/stem.5530100302","article-title":"Molecular structure of the IL-3, GM-CSF and IL-5 receptors","volume":"10","author":"Miyajima","year":"1992","journal-title":"Int. J. Cell Cloning"},{"key":"10.1016\/j.cyto.2023.156287_b0490","doi-asserted-by":"crossref","unstructured":"Martinez-Moczygemba Margarita, Huston David P, Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF, J. Allergy Clin. Immunol. 112 (4) (2003) 653\u2013665; quiz 666, doi: 10.1016\/S0091.","DOI":"10.1016\/j.jaci.2003.08.015"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0495","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V75.1.59.59","article-title":"Characterization of granulocyte-macrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukemia","volume":"75","author":"Onetto-Pothier","year":"1990","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cyto.2023.156287_b0500","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood.V74.7.2349.2349","article-title":"Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor show common biological effects and binding characteristics on human monocytes","volume":"74","author":"Elliott","year":"1989","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cyto.2023.156287_b0505","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1002\/eji.200636892","article-title":"Characterisation of the expression and function of the GM-CSF receptor alpha-chain in mice","volume":"37","author":"Marcela","year":"2007","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0510","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1006\/excr.1993.1151","article-title":"Differential expression of the common beta and specific alpha chains of the receptors for GM-CSF, IL-3, and IL-5 in endothelial cells","volume":"206","author":"Colotta","year":"1993","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0515","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0955-2235(94)90015-9","article-title":"Cytokine receptors and signal transduction","volume":"5","author":"Mui","year":"1994","journal-title":"Prog. Growth Factor Res."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0520","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood.V92.6.1989","article-title":"Saturation mutagenesis of the beta subunit of the human granulocyte-macrophage colony-stimulating factor receptor shows clustering of constitutive mutations, activation of ERK MAP kinase and STAT pathways, and differential beta subunit tyrosine phosphoryl","volume":"92","author":"Jenkins","year":"1998","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cyto.2023.156287_b0525","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/j.1460-2075.1992.tb05437.x","article-title":"Critical cytoplasmic domains of the common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors for growth signal transduction and tyrosine phosphorylation","volume":"11","author":"Sakamaki","year":"1992","journal-title":"EMBO J."},{"issue":"30","key":"10.1016\/j.cyto.2023.156287_b0530","doi-asserted-by":"crossref","first-page":"21856","DOI":"10.1016\/S0021-9258(19)36691-8","article-title":"Tyrosine phosphorylation of receptor beta subunits and common substrates in response to interleukin-3 and granulocyte-macrophage colony-stimulating factor","volume":"267","author":"Duronio","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0535","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/j.1460-2075.1995.tb07100.x","article-title":"Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs","volume":"14","author":"Mui","year":"1995","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0540","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/sj.emboj.7600948","article-title":"Growth factor pleiotropy is controlled by a receptor Tyr\/Ser motif that acts as a binary switch","volume":"25","author":"Guthridge Mark","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.cyto.2023.156287_b0545","doi-asserted-by":"crossref","unstructured":"Achuthan Adrian, Aslam Ahmad S M, Nguyen Quyen, Lam Pui-Yeng, Fleetwood Andrew J, Frye Ashlee T, et al., Glucocorticoids promote apoptosis of proinflammatory monocytes by inhibiting ERK activity, Cell Death Dis. 9 (3) (2018) 267, doi: 10.1038\/s41419-018-0332-4.","DOI":"10.1038\/s41419-018-0332-4"},{"issue":"12","key":"10.1016\/j.cyto.2023.156287_b0550","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood.V81.12.3193.3193","article-title":"Erythropoietin induces tyrosine phosphorylation and kinase activity of the c-fps\/fes proto-oncogene product in human erythropoietin-responsive cells","volume":"81","author":"Hanazono","year":"1993","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0555","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/j.1460-2075.1993.tb05809.x","article-title":"c-fps\/fes protein-tyrosine kinase is implicated in a signaling pathway triggered by granulocyte-macrophage colony-stimulating factor and interleukin-3","volume":"12","author":"Hanazono","year":"1993","journal-title":"EMBO J."},{"key":"10.1016\/j.cyto.2023.156287_b0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.cyto.2023.156287_b0565","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.4049\/jimmunol.175.10.6570","article-title":"Differential expression of IFN regulatory factor 4 gene in human monocyte-derived dendritic cells and macrophages","volume":"175","author":"Anne","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2023.156287_b0570","doi-asserted-by":"crossref","unstructured":"Gao Yan, Nish Simone A, Jiang Ruoyi, Hou Lin, Licona-Lim\u00f3n Paula, Weinstein Jason S, et al., Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells, Immunity 39 (4) (2013) 722\u2013732, doi: 10.1016\/j.immuni.2013.08.028.","DOI":"10.1016\/j.immuni.2013.08.028"},{"issue":"24","key":"10.1016\/j.cyto.2023.156287_b0575","doi-asserted-by":"crossref","first-page":"8981","DOI":"10.1073\/pnas.0402139101","article-title":"Critical roles of interferon regulatory factor 4 in CD11bhighCD8alpha- dendritic cell development","volume":"101","author":"Shoichi","year":"2004","journal-title":"PNAS"},{"key":"10.1016\/j.cyto.2023.156287_b0580","doi-asserted-by":"crossref","unstructured":"Van der Borght Katrien, Scott Charlotte L, Martens Liesbet, Sichien Dorine, Van Isterdael Gert, Nindl Veronika, et al., Myocarditis elicits dendritic cell and monocyte infiltration in the heart and self-antigen presentation by conventional type 2 dendritic cells, Front. Immunol. 9 (2018) 2714, doi: 10.3389\/fimmu.2018.02714.","DOI":"10.3389\/fimmu.2018.02714"},{"key":"10.1016\/j.cyto.2023.156287_b0585","doi-asserted-by":"crossref","unstructured":"Lee Ming-Chin, Lacey Derek C, Fleetwood Andrew J, Achuthan Adrian, Hamilton John A, Cook Andrew D., GM-CSF- and IRF4-dependent signaling can regulate myeloid cell numbers and the macrophage phenotype during inflammation, J. Immunol. 202 (10) (2019) 3033\u20133040, doi: 10.4049\/jimmunol.1801549.","DOI":"10.4049\/jimmunol.1801549"},{"issue":"11","key":"10.1016\/j.cyto.2023.156287_b0590","article-title":"Management of rheumatoid arthritis: an overview","volume":"10","author":"Andrei-Flavius","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cyto.2023.156287_b0595","doi-asserted-by":"crossref","unstructured":"Conforti Alessandro, Di Cola Ilenia, Pavlych Viktoriya, Ruscitti Piero, Berardicurti Onorina, Ursini Francesco, et al., Beyond the joints, the extra-articular manifestations in rheumatoid arthritis, Autoimmun. Rev. 20 (2) (2021) 102735, doi: 10.1016\/j.autrev.2020.102735.","DOI":"10.1016\/j.autrev.2020.102735"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0600","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/art.1780390116","article-title":"Synovial tissue macrophage populations and articular damage in rheumatoid arthritis","volume":"39","author":"Mulherin","year":"1996","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0605","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1172\/JCI113971","article-title":"Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions","volume":"83","author":"Xu","year":"1989","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0610","first-page":"121","article-title":"Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy","volume":"51","author":"Fiehn","year":"1992","journal-title":"Z. Rheumatol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0615","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.56.6.364","article-title":"Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice","volume":"56","author":"Campbell","year":"1997","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.cyto.2023.156287_b0620","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.4049\/jimmunol.161.7.3639","article-title":"Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice","volume":"161","author":"Campbell","year":"1998","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b0625","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1182\/blood.V74.8.2769.2769","article-title":"Correction of granulocytopenia in Felty\u2019s syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis","volume":"74","author":"Hazenberg","year":"1989","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0630","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.4049\/jimmunol.147.4.1238","article-title":"Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1","volume":"147","author":"Campbell","year":"1991","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.cyto.2023.156287_b0635","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood.V76.10.1989.1989","article-title":"Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor","volume":"76","author":"Leizer","year":"1990","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cyto.2023.156287_b0640","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrrheum.2009.178","article-title":"G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis","volume":"5","author":"Cornish Ann","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cyto.2023.156287_b0645","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12974-014-0201-8","article-title":"T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases","volume":"11","author":"Hugo","year":"2014","journal-title":"J. Neuroinflammation"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0650","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nri2550","article-title":"Autoimmune T cell responses in the central nervous system","volume":"9","author":"Joan","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0655","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4049\/jimmunol.178.1.39","article-title":"GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis","volume":"178","author":"Ponomarev Eugene","year":"2007","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0660","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/08923979809034820","article-title":"Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity","volume":"20","author":"Carrieri","year":"1998","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.cyto.2023.156287_b0665","doi-asserted-by":"crossref","unstructured":"Schnell Alexandra, Huang Linglin, Singer Meromit, Singaraju Anvita, Barilla Rocky M, Regan Brianna M L, et al., Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity, Cell 184 (26) (2021) 6281\u20136298.e23, doi: 10.1016\/j.cell.2021.11.018.","DOI":"10.1016\/j.cell.2021.11.018"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0670","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/j.1471-4159.2009.06432.x","article-title":"Granulocyte-macrophage colony-stimulating factor antibody suppresses microglial activity: implications for anti-inflammatory effects in Alzheimer\u2019s disease and multiple sclerosis","volume":"111","author":"Hemachandra","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cyto.2023.156287_b0675","doi-asserted-by":"crossref","unstructured":"Chang Yuna, Kim Ju Whi, Yang Siyoung, Chung Doo Hyun, Ko Jae Sung, Moon Jin Soo, et al., Increased GM-CSF-producing NCR- ILC3s and neutrophils in the intestinal mucosa exacerbate inflammatory bowel disease, Clin. Transl. Immunol. 10 (7) (2021), e1311, doi: 10.1002\/cti2.1311.","DOI":"10.1002\/cti2.1311"},{"key":"10.1016\/j.cyto.2023.156287_b0680","doi-asserted-by":"crossref","unstructured":"Castro-Dopico Tomas, Fleming Aaron, Dennison Thomas W, Ferdinand John R, Harcourt Katherine, Stewart Benjamin J, et al., GM-CSF calibrates macrophage defense and wound healing programs during intestinal infection and inflammation, Cell Rep. 32 (1) (2020) 107857, doi: 10.1016\/j.celrep.2020.107857.","DOI":"10.1016\/j.celrep.2020.107857"},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0685","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41419-019-1540-2","article-title":"ILC3 function as a double-edged sword in inflammatory bowel diseases","volume":"10","author":"Boning","year":"2019","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0690","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1073\/pnas.1912774117","article-title":"ECM1 is an essential factor for the determination of M1 macrophage polarization in IBD in response to LPS stimulation","volume":"117","author":"Yaguang","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.cyto.2023.156287_b0695","doi-asserted-by":"crossref","unstructured":"Guo Xiaohuan, Qiu Ju, Tu Tony, Yang Xuanming, Deng Liufu, Anders Robert A, et al., Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection, Immunity 40 (1) (2014) 25\u201339, doi: 10.1016\/j.immuni.2013.10.021.","DOI":"10.1016\/j.immuni.2013.10.021"},{"issue":"7452","key":"10.1016\/j.cyto.2023.156287_b0700","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature12240","article-title":"Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria","volume":"498","author":"Hepworth Matthew","year":"2013","journal-title":"Nature"},{"issue":"6238","key":"10.1016\/j.cyto.2023.156287_b0705","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.aaa4812","article-title":"Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4+ T cells","volume":"348","author":"Hepworth Matthew","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cyto.2023.156287_b0710","doi-asserted-by":"crossref","unstructured":"Mortha Arthur, Chudnovskiy Aleksey, Hashimoto Daigo, Bogunovic Milena, Spencer Sean P, Belkaid Yasmine, et al., Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis, Science 343 (6178) (2014) 1249288, doi: 10.1126\/science.1249288.","DOI":"10.1126\/science.1249288"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0715","doi-asserted-by":"crossref","first-page":"G455","DOI":"10.1152\/ajpgi.00409.2013","article-title":"Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn\u2019s disease","volume":"306","author":"Jan","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0720","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.chom.2010.01.006","article-title":"GM-CSF-facilitated dendritic cell recruitment and survival govern the intestinal mucosal response to a mouse enteric bacterial pathogen","volume":"7","author":"Yoshihiro","year":"2010","journal-title":"Cell Host Microbe"},{"issue":"12","key":"10.1016\/j.cyto.2023.156287_b0725","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/cr.2008.310","article-title":"The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation","volume":"18","author":"Yinghua","year":"2008","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0730","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ibd.20279","article-title":"Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis","volume":"14","author":"Sainathan Satheesh","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"issue":"9344","key":"10.1016\/j.cyto.2023.156287_b0735","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)11437-1","article-title":"Treatment of active Crohn\u2019s disease with recombinant human granulocyte-macrophage colony-stimulating factor","volume":"360","author":"Dieckgraefe Brian","year":"2002","journal-title":"Lancet (London, England)"},{"issue":"21","key":"10.1016\/j.cyto.2023.156287_b0740","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa041109","article-title":"Sargramostim in Crohn\u2019s Disease Study Group. Sargramostim for active Crohn\u2019s disease","volume":"352","author":"Korzenik Joshua","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.cyto.2023.156287_b0745","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1136\/gut.2008.165738","article-title":"Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn\u2019s disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"58","author":"Valentine","year":"2009","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0750","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/08977190500055836","article-title":"G-CSF: A key regulator of neutrophil production, but that\u2019s not all!","volume":"23","author":"Roberts","year":"2005","journal-title":"Growth Factors"},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0755","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0955-2235(05)80004-3","article-title":"Granulocyte colony-stimulating factor and its receptor","volume":"3","author":"Nagata","year":"1991","journal-title":"Prog. Growth Factor Res."},{"key":"10.1016\/j.cyto.2023.156287_b0760","first-page":"7517350","article-title":"Granulocyte colony-stimulating factor and its potential application for skeletal muscle repair and regeneration","volume":"2017","author":"Wright Craig","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0765","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s43440-020-00201-3","article-title":"Neuroprotection through G-CSF: recent advances and future viewpoints","volume":"73","author":"Vikrant","year":"2021","journal-title":"Pharmacol. Rep."},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0770","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jcp.1041160211","article-title":"Proliferative effects of purified granulocyte colony-stimulating factor (G-CSF) on normal mouse hemopoietic cells","volume":"116","author":"Metcalf","year":"1983","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0775","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000510352","article-title":"G-CSF and GM-CSF Are Different. Which One Is Better for COVID-19?","volume":"144","author":"Lazarus Hillard","year":"2021","journal-title":"Acta Haematol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0780","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/bjc.1987.295","article-title":"Phase I\/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer","volume":"56","author":"Bronchud","year":"1987","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.cyto.2023.156287_b0785","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood.V84.11.3885.bloodjournal84113885","article-title":"Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils","volume":"84","author":"de Haas","year":"1994","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0790","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood.V84.6.1737.1737","article-title":"Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization","volume":"84","author":"Lieschke","year":"1994","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.cyto.2023.156287_b0795","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2174\/092986708784567671","article-title":"Old friends in new constellations\u2013the hematopoetic growth factors G-CSF, GM-CSF, and EPO for the treatment of neurological diseases","volume":"15","author":"Maurer","year":"2008","journal-title":"Curr. Med. Chem."},{"issue":"22","key":"10.1016\/j.cyto.2023.156287_b0800","doi-asserted-by":"crossref","first-page":"8702","DOI":"10.1073\/pnas.87.22.8702","article-title":"Three different mRNAs encoding human granulocyte colony-stimulating factor receptor","volume":"87","author":"Fukunaga","year":"1990","journal-title":"PNAS"},{"key":"10.1016\/j.cyto.2023.156287_b0805","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.2741\/2041","article-title":"The interaction of G-CSF with its receptor","volume":"11","author":"Layton Judith","year":"2006","journal-title":"Front Biosci"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0810","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nsb0697-498","article-title":"Solution structure of an extracellular domain containing the WSxWS motif of the granulocyte colony-stimulating factor receptor and its interaction with ligand","volume":"4","author":"Yamasaki","year":"1997","journal-title":"Nat. Struct. Biol."},{"issue":"12","key":"10.1016\/j.cyto.2023.156287_b0815","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.biocel.2009.08.011","article-title":"Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more","volume":"41","author":"Clifford","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0820","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.V93.1.113","article-title":"Tyrosine-dependent and -independent mechanisms of STAT3 activation by the human granulocyte colony-stimulating factor (G-CSF) receptor are differentially utilized depending on G-CSF concentration","volume":"93","author":"Ward","year":"1999","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.cyto.2023.156287_b0825","doi-asserted-by":"crossref","first-page":"8622","DOI":"10.1073\/pnas.87.21.8622","article-title":"Src homology region 2 domains direct protein-protein interactions in signal transduction","volume":"87","author":"Moran","year":"1990","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b0830","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1161\/STROKEAHA.107.506816","article-title":"Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia","volume":"39","author":"Jens","year":"2008","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0835","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/01.STR.0000057814.70180.17","article-title":"Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia","volume":"34","author":"Sch\u00e4bitz","year":"2003","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b0840","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1172\/JCI23559","article-title":"The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis","volume":"115","author":"Armin","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0845","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/cid\/ciab534","article-title":"The effect of neutropenia and filgrastim (G-CSF) on cancer patients with coronavirus disease 2019 (COVID-19) infection","volume":"74","author":"Zhang Allen","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0850","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamainternmed.2020.5503","article-title":"Effect of recombinant human granulocyte colony-stimulating factor for patients with coronavirus disease 2019 (COVID-19) and lymphopenia: a randomized clinical trial","volume":"181","author":"Lin-Ling","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"15","key":"10.1016\/j.cyto.2023.156287_b0855","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.2146\/ajhp090325","article-title":"Use of granulocyte colony-stimulating factor in patients with severe sepsis or septic shock","volume":"67","author":"Mohammad","year":"2010","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.cyto.2023.156287_b0860","unstructured":"Dos Santos Cruz GJ, Loraine H, Zhang JG, Clark KL, Davis RJ. G-CSF and GM-CSF are differentially released from primary human lung cells in response to pro-inflammatory cytokines (abstract). n.d."},{"key":"10.1016\/j.cyto.2023.156287_b0865","doi-asserted-by":"crossref","unstructured":"Wang Hao, FitzPatrick Meaghan, Wilson Nicholas J, Anthony Desiree, Reading Patrick C, Satzke Catherine, et al., CSF3R\/CD114 mediates infection-dependent transition to severe asthma, J. Allergy Clin. Immunol. 143 (2) (2019) 785\u2013788.e6, doi: 10.1016\/j.jaci.2018.10.001.","DOI":"10.1016\/j.jaci.2018.10.001"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0870","doi-asserted-by":"crossref","first-page":"17732","DOI":"10.1038\/s41598-019-54053-w","article-title":"G-CSFR antagonism reduces neutrophilic inflammation during pneumococcal and influenza respiratory infections without compromising clearance","volume":"9","author":"Hao","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2023.156287_b0875","doi-asserted-by":"crossref","unstructured":"Tsantikos Evelyn, Lau Maverick, Castelino Cassandra Mn, Maxwell Mhairi J, Passey Samantha L, Hansen Michelle J, et al., Granulocyte-CSF links destructive inflammation and comorbidities in obstructive lung disease, J. Clin. Invest. 128 (6) (2018) 2406\u20132418, doi: 10.1172\/JCI98224.","DOI":"10.1172\/JCI98224"},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0880","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1378\/chest.121.5.1716","article-title":"Common features in the onset of ARDS after administration of granulocyte colony-stimulating factor","volume":"121","author":"Hiroyuki","year":"2002","journal-title":"Chest"},{"issue":"3\u20134","key":"10.1016\/j.cyto.2023.156287_b0885","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/10428199809059222","article-title":"Involvement of granulocyte colony-stimulating factor in proliferation of adult T-cell leukemia cells","volume":"31","author":"Matsushita","year":"1998","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0890","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5551\/jat.2279","article-title":"Appropriate doses of granulocyte-colony stimulating factor reduced atherosclerotic plaque formation and increased plaque stability in cholesterol-fed rabbits","volume":"17","author":"Taro","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b0895","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ahj.2008.03.024","article-title":"Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials","volume":"156","author":"Ahmed","year":"2008","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b0900","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10557-007-6072-9","article-title":"A meta-analysis of stem cell mobilization by granulocyte colony-stimulating factor in the treatment of acute myocardial infarction","volume":"22","author":"Lin","year":"2008","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0905","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/hrt.2006.111385","article-title":"Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis","volume":"94","author":"Ince","year":"2008","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.cyto.2023.156287_b0910","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.clinthera.2007.11.008","article-title":"Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials","volume":"29","author":"Sheng","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.cyto.2023.156287_b0915","doi-asserted-by":"crossref","unstructured":"Moazzami Kasra, Roohi Aria, Moazzami Bobak. Granulocyte colony stimulating factor therapy for acute myocardial infarction, Cochrane Database Syst. Rev. 2013 (5) (2013) CD008844, doi: 10.1002\/14651858.CD008844.pub2.","DOI":"10.1002\/14651858.CD008844.pub2"},{"issue":"15","key":"10.1016\/j.cyto.2023.156287_b0920","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2007.11.073","article-title":"Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis","volume":"51","author":"Dietlind","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Suppl 7","key":"10.1016\/j.cyto.2023.156287_b0925","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1399-3046.2005.00444.x","article-title":"Granulocyte-colony stimulating factor primed bone marrow and granulocyte-colony stimulating factor mobilized peripheral blood stem cells are equivalent for engraftment: which to choose?","volume":"9","author":"Elfenbein","year":"2005","journal-title":"Pediatr. Transplant."},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0930","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi Hasan","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cyto.2023.156287_b0935","doi-asserted-by":"crossref","unstructured":"Rizk John G, Kalantar-Zadeh Kamyar, Mehra Mandeep R, Lavie Carl J, Rizk Youssef, Forthal Donald N., Pharmaco-immunomodulatory therapy in COVID-19, Drugs 80 (13) (2020) 1267\u20131292, doi: 10.1007\/s40265-020-01367-z.","DOI":"10.1007\/s40265-020-01367-z"},{"key":"10.1016\/j.cyto.2023.156287_b0940","doi-asserted-by":"crossref","unstructured":"Kim Jae Seok, Lee Jun Young, Yang Jae Won, Lee Keum Hwa, Effenberger Maria, Szpirt Wladimir, et al., Immunopathogenesis and treatment of cytokine storm in COVID-19, Theranostics 11 (1) (2021) 316\u2013329, doi: 10.7150\/thno.49713.","DOI":"10.7150\/thno.49713"},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0945","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel Trevor","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cyto.2023.156287_b0950","doi-asserted-by":"crossref","unstructured":"Galv\u00e1n-Rom\u00e1n Jos\u00e9 Mar\u00eda, Rodr\u00edguez-Garc\u00eda Sebasti\u00e1n C, Roy-Vallejo Emilia, Marcos-Jim\u00e9nez Ana, S\u00e1nchez-Alonso Santiago, Fern\u00e1ndez-D\u00edaz Carlos, et al., IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study, J. Allergy Clin. Immunol. 147 (1) (2021) 72\u201380.e8, doi: 10.1016\/j.jaci.2020.09.018.","DOI":"10.1016\/j.jaci.2020.09.018"},{"issue":"7","key":"10.1016\/j.cyto.2023.156287_b0955","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.4049\/jimmunol.2001126","article-title":"IL-1 receptor antagonist anakinra in the treatment of COVID-19 acute respiratory distress syndrome: a retrospective, observational study","volume":"206","author":"Marco","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2023.156287_b0960","doi-asserted-by":"crossref","unstructured":"Cauchois Rapha\u00ebl, Koubi Marie, Delarbre David, Manet C\u00e9cile, Carvelli Julien, Blasco Valery Benjamin, et al., Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19, Proc. Natl. Acad. Sci. U. S. A. 117 (32) (2020) 18951\u201318953, doi: 10.1073\/pnas.2009017117.","DOI":"10.1073\/pnas.2009017117"},{"key":"10.1016\/j.cyto.2023.156287_b0965","doi-asserted-by":"crossref","unstructured":"Feldmann Marc, Maini Ravinder N, Woody James N, Holgate Stephen T, Winter Gregory, Rowland Matthew, et al., Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed, Lancet (London, England) 395 (10234) (2020) 1407\u20131409, doi: 10.1016\/S0140-6736(20)30858-8.","DOI":"10.1016\/S0140-6736(20)30858-8"},{"issue":"9","key":"10.1016\/j.cyto.2023.156287_b0970","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L","article-title":"Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology","volume":"31","author":"Hussell","year":"2001","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b0975","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/mpat.1995.0056","article-title":"Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia","volume":"19","author":"Peper","year":"1995","journal-title":"Microb. Pathog."},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b0980","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis","volume":"39","author":"Chousterman Benjamin","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.cyto.2023.156287_b0985","doi-asserted-by":"crossref","unstructured":"Locatelli Franco, Jordan Michael B, Allen Carl, Cesaro Simone, Rizzari Carmelo, Rao Anupama, et al., Emapalumab in children with primary hemophagocytic lymphohistiocytosis, N Engl J Med 382 (19) (2020) 1811\u20131822, doi: 10.1056\/NEJMoa1911326.","DOI":"10.1056\/NEJMoa1911326"},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b0990","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","article-title":"Neutralization of IFN-\u03b3 reverts clinical and laboratory features in a mouse model of macrophage activation syndrome","volume":"141","author":"Giusi","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2023.156287_b0995","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.4049\/jimmunol.157.11.5049","article-title":"Lethal synergism between influenza infection and staphylococcal enterotoxin B in mice","volume":"157","author":"Zhang","year":"1996","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.cyto.2023.156287_b1000","first-page":"2134","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies","volume":"54","author":"Giulio","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b1005","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Pierre","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b1010","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","article-title":"Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes","volume":"55","author":"Torbj\u00f6rn","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b1015","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Margherita","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2023.156287_b1020","article-title":"Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study","volume":"24(1):688","author":"Kooistra Emma","year":"2020","journal-title":"Crit. Care"},{"issue":"11","key":"10.1016\/j.cyto.2023.156287_b1025","doi-asserted-by":"crossref","first-page":"e28581","DOI":"10.1002\/pbc.28581","article-title":"The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis","volume":"67","author":"Sakshi","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b1030","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Giulio","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b1035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/1744666X.2019.1707664","article-title":"Canakinumab for the treatment of adult-onset Still\u2019s disease","volume":"16","author":"Paolo","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.cyto.2023.156287_b1040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijid.2020.12.073","article-title":"Canakinumab as treatment for COVID-19-related pneumonia: a prospective case-control study","volume":"104","author":"Daniele","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b1045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jama.2021.9508","article-title":"Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial","volume":"326","author":"Roberto","year":"2021","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b1050","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting Interleukin-6 Signaling in Clinic","volume":"50","author":"Sujin","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2023.156287_b1055","doi-asserted-by":"crossref","unstructured":"van Rhee Frits, Voorhees Peter, Dispenzieri Angela, Foss\u00e5 Alexander, Srkalovic Gordan, Ide Makoto, et al., International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease, Blood 132 (20) (2018) 2115\u20132124, doi: 10.1182\/blood-2018-07-862334.","DOI":"10.1182\/blood-2018-07-862334"},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b1060","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Chelsea","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.cyto.2023.156287_b1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110698","article-title":"The role of Interleukin 6 inhibitors in therapy of severe COVID-19","volume":"131","author":"Nasonov","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b1070","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1186\/s13063-020-04633-3","article-title":"Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Caballero Bermejo Antonio","year":"2020","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b1075","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1186\/s13063-020-04588-5","article-title":"Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Rosario","year":"2020","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b1080","article-title":"Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy","volume":"8","author":"Vincenzo","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"16","key":"10.1016\/j.cyto.2023.156287_b1085","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically Ill patients with covid-19","volume":"384","author":"Investigators","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2023.156287_b1090","article-title":"IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study","author":"Gritti","year":"2020","journal-title":"MedRxiv Prepr Serv Heal Sci"},{"key":"10.1016\/j.cyto.2023.156287_b1095","doi-asserted-by":"crossref","unstructured":"Stark George R, Cheon HyeonJoo, Wang Yuxin, Responses to cytokines and interferons that depend upon JAKs and STATs, Cold Spring Harb. Perspect. Biol. 10 (1) (2018), doi: 10.1101\/cshperspect.a028555.","DOI":"10.1101\/cshperspect.a028555"},{"issue":"9","key":"10.1016\/j.cyto.2023.156287_b1100","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with covid-19","volume":"384","author":"Kalil Andre","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10223","key":"10.1016\/j.cyto.2023.156287_b1105","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Peter","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"13","key":"10.1016\/j.cyto.2023.156287_b1110","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Rupali","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b1115","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/j.jaad.2020.03.099","article-title":"The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"82","author":"Danielle","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b1120","doi-asserted-by":"crossref","first-page":"e2013136","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial","volume":"3","author":"Deftereos Spyridon","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cyto.2023.156287_b1125","doi-asserted-by":"crossref","unstructured":"Lazarus Hillard M, Ragsdale Carolyn E, Gale Robert Peter, Lyman Gary H. Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator. A drug before its time? Front. Immunol. 12 (2021) 706186, doi: 10.3389\/fimmu.2021.706186.","DOI":"10.3389\/fimmu.2021.706186"},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b1130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1164\/rccm.2009005","article-title":"A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction","volume":"166","author":"Presneill Jeffrey","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b1135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CCM.0b013e31822d7bf0","article-title":"A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury","volume":"40","author":"Robert","year":"2012","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.cyto.2023.156287_b1140","doi-asserted-by":"crossref","unstructured":"Orozco H\u00e9ctor, Arch Jorge, Medina-Franco Heriberto, Pantoja Juan P, Gonz\u00e1lez Quint\u00edn H, Vilatoba Mario, et al., Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial, Arch Surg 141 (2) (2006) 150\u2013153; discussion 154, doi: 10.1001\/archsurg.141.2.150.","DOI":"10.1001\/archsurg.141.2.150"},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b1145","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2665-9913(20)30185-5","article-title":"GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?","volume":"2","author":"Giulio","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.cyto.2023.156287_b1150","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2012-202450","article-title":"Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis","volume":"72","author":"Burmester Gerd","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2023.156287_b1155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/DDDT.S104233","article-title":"Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date","volume":"11","author":"Chiara","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"issue":"8","key":"10.1016\/j.cyto.2023.156287_b1160","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2665-9913(20)30170-3","article-title":"GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study","volume":"2","author":"Giacomo","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.cyto.2023.156287_b1165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","article-title":"Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study","volume":"76","author":"Corrado","year":"2020","journal-title":"Eur. J. Intern. Med."},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b1170","article-title":"Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE)","volume":"8","author":"Marta","year":"2020","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/j.cyto.2023.156287_b1175","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1212\/NXI.0000000000000117","article-title":"Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis","volume":"2","author":"Constantinescu Cris","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"6","key":"10.1016\/j.cyto.2023.156287_b1180","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/annrheumdis-2013-204816","article-title":"MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib\/IIa randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"74","author":"Frank","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b1185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2213-2600(21)00494-X","article-title":"Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial","volume":"10","author":"Zelalem","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b1190","article-title":"A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)","volume":"61","author":"Jatin","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cyto.2023.156287_b1195","unstructured":"FDA, FDA Approves Emergency IND Use of Humanigen\u2019s Lenzilumab for Compassionate Use in COVID-19 Patients. Available from: <https:\/\/www.humanigen.com\/press\/FDA-Approves-Emergency-IND-Use-of-Humanigen\u2019s-Lenzilumab-for-Compassionate-Use-in-COVID-19-Patients> (accessed April 11, 2020) 2020."},{"key":"10.1016\/j.cyto.2023.156287_b1200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12861-015-0094-5","article-title":"The developmental basis of mesenchymal stem\/stromal cells (MSCs)","volume":"15","author":"Guojun","year":"2015","journal-title":"BMC Dev. Biol"},{"issue":"5","key":"10.1016\/j.cyto.2023.156287_b1205","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14653240500319234","article-title":"Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement","volume":"7","author":"Horwitz","year":"2005","journal-title":"Cytotherapy"},{"key":"10.1016\/j.cyto.2023.156287_b1210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/sci-2020-022","article-title":"Cellular therapy: shafts of light emerging for COVID-19","volume":"7","author":"Madhan","year":"2020","journal-title":"Stem Cell Investig"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b1215","article-title":"Role of human mesenchymal stem cells in regenerative therapy","volume":"10","author":"Jayavardini","year":"2020","journal-title":"Cells"},{"issue":"20","key":"10.1016\/j.cyto.2023.156287_b1220","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1089\/scd.2016.0184","article-title":"Effect of mesenchymal stromal cells on T cells in a septic context: immunosuppression or immunostimulation?","volume":"26","author":"S\u00e9bastien","year":"2017","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.cyto.2023.156287_b1225","first-page":"12(July)","article-title":"Regulation of inflammatory cytokine storms by mesenchymal stem cells","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b1230","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11373-004-8183-7","article-title":"T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression","volume":"12","author":"Elena","year":"2005","journal-title":"J. Biomed. Sci."},{"issue":"11","key":"10.1016\/j.cyto.2023.156287_b1235","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.exphem.2008.06.008","article-title":"MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge","volume":"36","author":"Keung","year":"2008","journal-title":"Exp. Hematol."},{"issue":"12","key":"10.1016\/j.cyto.2023.156287_b1240","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/stem.2094","article-title":"Insensitivity of human ips cells-derived mesenchymal stem cells to interferon-\u03b3-induced HLA expression potentiates repair efficiency of hind limb ischemia in immune humanized NOD scid gamma mice","volume":"33","author":"Yue-Qi","year":"2015","journal-title":"Stem Cells"},{"issue":"12","key":"10.1016\/j.cyto.2023.156287_b1245","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1089\/scd.2020.0080","article-title":"Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19","volume":"29","author":"Vikram","year":"2020","journal-title":"Stem Cells Dev."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b1250","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/stem.1504","article-title":"Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice","volume":"32","author":"Ying-Gang","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.cyto.2023.156287_b1255","doi-asserted-by":"crossref","unstructured":"Bobati Shreedevi S, Naik Karkal Ravishankar, Therapeutic plasma exchange - an emerging treatment modality in patients with neurologic and non-neurologic diseases, J Clin Diagn Res 11 (8) (2017) EC35\u2013 EC37, doi: 10.7860\/JCDR\/2017\/27073.10480.","DOI":"10.7860\/JCDR\/2017\/27073.10480"},{"key":"10.1016\/j.cyto.2023.156287_b1260","doi-asserted-by":"crossref","unstructured":"Gucyetmez Bulent, Atalan Hakan Korkut, Sertdemir Ibrahim, Cakir Ulkem, Telci Lutfi, COVID-19 Study Group, Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study, Crit Care 24 (1) (2020) 492, doi: 10.1186\/s13054-020-03215-8.","DOI":"10.1186\/s13054-020-03215-8"},{"key":"10.1016\/j.cyto.2023.156287_b1265","article-title":"Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19","volume":"175","author":"Larry","year":"2020","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b1270","doi-asserted-by":"crossref","first-page":"e0244853","DOI":"10.1371\/journal.pone.0244853","article-title":"Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study","volume":"16","author":"Mehmood","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b1275","first-page":"11","article-title":"A promising anti-cytokine-storm targeted therapy for COVID-19: the artificial-liver blood-purification system","volume":"7","author":"Zhang Yimin","year":"2021","journal-title":"Eng (Beijing, China)"},{"key":"10.1016\/j.cyto.2023.156287_b1280","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ijid.2020.05.065","article-title":"Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification","volume":"96","author":"Wang Qiang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b1285","first-page":"147","article-title":"Management of COVID-19: the Zhejiang experience","volume":"49","author":"Kaijin","year":"2020","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.cyto.2023.156287_b1290","article-title":"Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19","volume":"214","author":"Jie","year":"2020","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156287_b1295","first-page":"106","article-title":"Expert recommendations on blood purification treatment protocol for patients with severe COVID-19","volume":"6","author":"Xiang-Hong","year":"2020","journal-title":"Chronic Dis Transl Med"},{"key":"10.1016\/j.cyto.2023.156287_b1300","article-title":"Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19","volume":"292","author":"Raman","year":"2021","journal-title":"Virus Res."},{"key":"10.1016\/j.cyto.2023.156287_b1305","doi-asserted-by":"crossref","unstructured":"de Ligt Marlies, Hesselink Matthijs K C, Jorgensen Johanna, Hoebers Nicole, Blaak Ellen E, Goossens Gijs H, Resveratrol supplementation reduces ACE2 expression in human adipose tissue, Adipocyte 10 (1) (2021) 408\u2013411, doi: 10.1080\/21623945.2021.1965315.","DOI":"10.1080\/21623945.2021.1965315"},{"issue":"3","key":"10.1016\/j.cyto.2023.156287_b1310","article-title":"SARS-CoV-2 disease adjuvant therapies and supplements breakthrough for the infection prevention","volume":"9","author":"Danilo","year":"2021","journal-title":"Microorganisms"},{"issue":"12","key":"10.1016\/j.cyto.2023.156287_b1315","doi-asserted-by":"crossref","first-page":"6530","DOI":"10.1002\/ptr.7228","article-title":"Combination of natural antivirals and potent immune invigorators: a natural remedy to combat COVID-19","volume":"35","author":"Ajmal","year":"2021","journal-title":"Phytother. Res."},{"issue":"7","key":"10.1016\/j.cyto.2023.156287_b1320","doi-asserted-by":"crossref","first-page":"e039519","DOI":"10.1136\/bmjopen-2020-039519","article-title":"Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial","volume":"10","author":"Fang","year":"2020","journal-title":"BMJ Open"},{"issue":"29","key":"10.1016\/j.cyto.2023.156287_b1325","doi-asserted-by":"crossref","first-page":"e26705","DOI":"10.1097\/MD.0000000000026705","article-title":"Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: a single center experience from Pune, Western India","volume":"100","author":"Ameet","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.cyto.2023.156287_b1330","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","article-title":"Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases","volume":"26","author":"Lisa","year":"2012","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.cyto.2023.156287_b1335","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/annrheumdis-2020-217712","article-title":"Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome","volume":"79","author":"Mirko","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.cyto.2023.156287_b1340","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/rheumatology\/keaa217","article-title":"Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease","volume":"59","author":"Silvia","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.cyto.2023.156287_b1345","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/CCM.0000000000003262","article-title":"Corticosteroids in sepsis: an updated systematic review and meta-analysis","volume":"46","author":"Bram","year":"2018","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.cyto.2023.156287_b1350","doi-asserted-by":"crossref","unstructured":"Ramamoorthy Sivapriya, Cidlowski John A., Corticosteroids: mechanisms of action in health and disease, Rheum Dis Clin North Am 42 (1) (2016), 15\u201331, vii, doi: 10.1016\/j.rdc.2015.08.002.","DOI":"10.1016\/j.rdc.2015.08.002"},{"issue":"30","key":"10.1016\/j.cyto.2023.156287_b1355","doi-asserted-by":"crossref","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","article-title":"Shattering barriers toward clinically meaningful MSC therapies","volume":"6","author":"Oren","year":"2020","journal-title":"Sci. Adv."},{"issue":"20","key":"10.1016\/j.cyto.2023.156287_b1360","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon Calvin","year":"2020","journal-title":"J. Biol. Chem."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623001655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623001655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:52:52Z","timestamp":1760910772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466623001655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":272,"alternative-id":["S1043466623001655"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156287","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging aspects of cytokine storm in COVID-19: The role of proinflammatory cytokines and therapeutic prospects","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156287"}}